Mira Jung

Developing Selective HDAC Inhibitors

Mira Jung, PhD, received her doctorate in molecular biology and microbiology at the University of Kansas, and completed postdoctoral training in molecular radiation biology at Georgetown University. Dr. Jung’s research focuses on understanding the molecular mechanisms underlying radiation sensitivity. Her research contributions include findings that NF-kB activation is critical for cell survival in patients with the human radiation sensitivity syndrome ataxia-telangiectasia and that the mutated AT gene product, ATM, is involved in this process. Recently, her research has made an important breakthrough in the identification of histone deacetylase (HDAC) inhibitors as radiosensitizing agents for cancer cells in vitro and in vivo. In studies related to signal transduction, she found that chromatin structure modification serves as a radiation sensitivity mechanism. Dr. Jung’s overall research goals are to determine cellular radiation response mechanisms, to identify targets for therapeutic gain, and to develop strategies for human cancer treatment.